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ABSTRACT 
Prostate cancer is the most common malignancy in Sweden with about 9000 new cases 
diagnosed every year. New markers are needed to improve diagnostic accuracy. The 
most commonly used tissue-biomarkers are basal cell markers and AMACR, often used 
in combination. We identified three potential tissue biomarkers, CYCS, ICK and 
IKBKB, by using the Human Protein Atlas database and investigated their diagnostic 
accuracy. The potential of these biomarkers was also compared with AMACR. 
Immunohistochemical analysis of the markers was performed on a tissue microarray 
(TMA) consisting of tissue from 40 prostate specimens, including benign prostatic 
tissue, atrophy, high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate 
cancer.  In addition, qRT-PCR analysis of malignant and benign frozen tissue samples 
from 32 radical prostatectomy specimens was performed. All four biomarkers showed a 
higher protein expression in prostate cancer and HGPIN than in benign tissue. The 
prognostic accuracy was highest for AMACR, but the results indicate that in some 
cases CYCS, ICK and IKBKB may serve as additional diagnostic markers.  
 
It is known that prognostic information can also be derived from tumor stroma. The 
prognostic value of stromal expression of PDGFRβ was therefore evaluated by 
immunohistochemical analysis of PDGFRβ on a TMA containing cancer and non-
malignant tissue from more than 300 prostate cancer patients. The association between 
stromal staining intensity and a number of clinical characteristics were then analyzed. 
Expression of PDGFRβ in non-malignant and tumor stroma was associated with high 
Gleason grade and reduced cancer specific survival. 
 
Cancer associated fibroblasts (CAFs) are found in many solid tumors and promote 
tumor growth and progression. Identification and inhibition of molecules mediating 
these interactions constitute an attractive strategy for development of new cancer 
therapies. By comparative analyses of CAFs and normal fibroblasts from prostate tissue 
we have identified a number of genes upregulated in prostate CAFs. CXCL14, an 
orphan chemokine, was the most upregulated transcript. Overexpression of CXCL14 in 
fibroblasts increased their proliferation and migratory capacity. Also over-expression in 
fibroblasts of CAF led to increased ability of these cells to stimulate proliferation and 
migration of prostate cancer cells. Furthermore, fibroblasts overexpressing CXCL14 
enhanced tumor growth, vascularisation and macrophage infiltration in a stroma-
dependent prostate cancer model. 
 
Another transcript identified to be upregulated in prostate CAFs was GDF15, a member 
of the TGFβ superfamily. GDF15 was shown to stimulate fibroblast proliferation and 
enhanced growth, migration and invasion of prostate cancer cells. Fibroblasts over-
expresssing GDF15 was also able to stimulate prostate xenograft growth when co-
injected with prostate cancer cells. Interestingly, these fibroblasts also increased the 
ability of tumor xenograft to promote growth at a distant site suggesting direct or in-
direct systemic pro-tumoral effects of fibroblast-derived GDF15. 
 
These studies thus identify a set of new diagnostic and prognostic markers for prostate 
cancer and stroma-derived potential therapeutic targets. 
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1 INTRODUCTION 
Around 50 000 persons are diagnosed with cancer and approximately 20 000 persons 
die from cancer in Sweden every year. One out of three persons in Sweden will develop 
cancer during their lifetime and cancer is the second most common cause of death, 
following cardiovascular disease.  Breast and prostate cancer are the most common 
cancers in Sweden, making up one third of all cases.  
 
The incidence of both breast and prostate cancer is increasing, as well as skin cancer 
and lung cancer among women.  Some of the increase might be due to an older 
population, and other explanations are increased smoking among women and higher 
exposure to the sun. Cervix and gastric cancer are decreasing, likely due to screening 
for cervix cancer, improved diet and less Helicobacter pylori infections. There are a 
number of known risk factors for cancer. Smoking is the most important risk factor and 
it is estimated that 20% of all cancer cases can be connected to smoking. Examples of 
other known risk factors are alcohol, obesity, foodstuff, exposure to chemical or 
physical carcinogens and virus infections.  Also, the risk of developing some cancers 
can be increased due to genetic predispositions [1].  
 
Cancer is a consequence of genetic alterations, including point mutations, deletions, 
amplifications, translocations and epigenetic changes. These alterations in turn provide 
the cells with new capacities which make them able to circumvent their normally 
strictly controlled homeostasis. Hanahan and Weinberg identified six attributes 
necessary for tumor development that are shared by most tumors: limitless replicative 
potential, evasion of apoptosis, self sufficiency in growth signals, insensitivity to anti-
growth signals, sustained angiogenesis and capacity to invade tissue and metastasize 
[2].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The hallmarks of cancer.  
Figure adapted from [2]. 
 
Lately, additional hallmarks of cancer have been discussed as being equally important 
for cancer. The tumor stroma is being increasingly recognized as an important factor 
for tumor development, progression and metastasis [3]. 
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1.1 PROSTATE CANCER 
Prostate cancer is the most common form of cancer in Sweden. Around 9 000 new 
cases are diagnosed yearly. Approximately 50 percent of the patients are over 70 years 
of age when they are diagnosed, and the disease is extremely rare before 40 years of 
age [4]. 
 
 
1.1.1 The prostate gland 
The prostate is a gland located under the urinary bladder, surrounding the upper part of 
the urethra. The prostate produces a secretion containing citrate, acid phosphatase and 
several proteolytic enzymes (e.g. PSA). This secretion contributes to seminal fluid and 
raises the pH of semen and improves motility and fertility of sperm.   
 
The prostate gland is small before puberty, but under the influence of testosterone it 
grows to the size of a chestnut [5]. 
 
The prostate gland is composed of glands surrounded by a fibromuscular stroma. The 
prostate is divided into three anatomical zones: the peripheral zone which contains the 
main prostatic glands and where most of the glandular tissue is located in the young 
man, the central zone containing about 25 percent glandular tissue and the transition 
zone which surrounds the urethra.  
 
Benign prostatic hyperplasia, a condition that leads to obstruction of the urinary tract, 
occurs mainly in the transition zone, whereas prostate cancer most commonly develops 
in the peripheral zone [6]. 
 
 
1.1.2 Prostate tumors 
Prostate carcinoma is usually an adenocarcinoma that develops from the prostatic 
glands [7]. Among clinically detected cancers, 70 - 80% arise in the peripheral zone 
and 15 - 25% are of transition zone origin while only 5 - 10% are assumed to be of 
central zone origin [8]. 
 
Prostate cancer can spread directly to the bladder and adjacent tissues or via the 
lymphatic or blood vessels to lymph nodes and distant organs [7]. The most common 
site for prostate cancer metastasis is bone [4]. 
 
 
1.1.3 Epidemiology and genetics 
The risk of developing prostate cancer increases with age. Most patients are diagnosed 
after 65 years of age and the mean age of diagnosis is 72-74 years [9]. 
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Many different environmental factors and their effect on the risk of developing prostate 
cancer have been studied. Epidemiological studies have shown that tomatoes, selenium, 
vitamin E and green tea decrease the risk of developing prostate cancer, whereas a high 
intake of red and processed meat and dietary fat is associated with increased risk [10].  
 
Race can also influence the risk of developing prostate cancer. When analyzing the 
American population, African-American men were found to have a 2-fold higher risk 
of prostate cancer as compared to Caucasians, while the risk for Japanese men was 2/3 
of the risk of Caucasian men [11]. 
 
Hereditary factors also influence the risk to develop prostate cancer. An affected first-
grade relative will increase the risk 2-3-fold. The genetic component of hereditary 
prostate cancer is quite complex, and several different chromosomal regions and loci 
are known to be involved [9,12]. No single gene can therefore be used to predict risk of 
developing prostate cancer. 
 
A number of SNPs associated with the risk of developing prostate cancer have been 
identified. Most variants indicate only a small risk increase, but combining data from 
several SNPs might provide important information in predicting prostate cancer risk 
[13]. 
 
Somatic genetic aberrations found in prostate cancer include fusions of ETS 
transcription factors members, the most common variant being TMPRSS2-ERG. ETS 
fusion genes are found in approximately 60-70 percent of prostate cancers [14]. 
 
 
1.1.4 Detection and grading 
The most widely used biomarker for detection of prostate cancer is the serine protease 
PSA. The expression of PSA is controlled by androgens, and the expression is 
restricted to the prostate. During normal conditions, PSA is secreted into the seminal 
fluid and only a very small amount will leak out to the blood stream. Prostate cancer or 
other diseases of the prostate might cause a release of PSA to the blood. Detection of 
elevated levels of PSA in serum is therefore used as a tool for diagnosing prostate 
cancer. Since elevation of PSA is not specific for cancer but can also be caused by 
other disesases of the prostate, histopathological examination of biopsies are needed for 
the final diagnosis [15]. In addition to the actual PSA level, also other factors such as 
PSA density (PSA/prostate volume), PSA velocity (yearly change of PSA level) and 
PSA doubling time can be used as prognostic markers [16]. The use of PSA screening 
has been shown to reduce mortality in prostate cancer but the method also generates 
problems with overdetection and overtreatment [17].  Examples of other biomarkers in 
the serum are PAP, EPCA and EPCA-2 [16]. 
 
Cancer is diagnosed based on morphological analysis of biopsies using light 
microscopy. If morphological changes are insufficient for a conclusive diagnosis the 
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biopsies can be further analyzed with immunohistochemistry. Since the basal layer is 
lost in prostate cancer, detection of basal cells with high-molecular weight keratin or 
p63 is commonly used as a diagnostic tool. AMACR, which is an enzyme involved in 
fatty acid metabolism, is sometimes also used as a biomarker for cancer. However, not 
all cancers are positive for AMACR and the protein is also expressed in some benign 
lesions [18].  
 
The Gleason grading method is the most established prognostic indicator for prostate 
cancer. The system is based on histology, where the growth patterns of prostate cancer 
is analyzed with light microscopy of hematoxylin and eosin stained tissue sections. The 
growth pattern is graded from 1 to 5 according to glandular achitecture. A Gleason 
score (from 2 to 10) is obtained by adding the two predominant Gleason grades [19]. 
Increased Gleason score is associated with a number of prognostic features, such as 
lymph node invasion, tumor size and stage, with biochemical recurrence after radical 
prostatectomy and with disease-specific survival in patients on deferred treatment 
[19,20,21].  
 
Figure 2. The Gleason grading system.  
Figure adapted from [19] 
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1.1.5 Treatment 
In Sweden, older patients with an expected remaining lifetime of less than 10 years, 
prostate cancer without symptoms is not always treated. Active surveillance, i.e. careful 
monitoring of disease progress and deferred treatment may be an alternative to 
immediate therapy in selected cases [18].  
 
Radical prostatectomy, where the prostate is surgically removed, is an efficient way of 
treating localized disease. Radiotherapy is an alternative treatment, where the prostate 
is kept intact. In both cases, side effects such as impotence can occur.  
 
Since prostate cancer cells normally are androgen dependent, deprivation of androgen 
can be used in combination with other treatments in all stages of the disease. This can 
be achieved, either by reducing the production of testosteron through chemical or 
surgical castration or by treatment with anti-androgens or estrogen. Most prostate 
tumors initially respond to this treatment, but eventually advanced cancers usually 
become androgen independent.  
 
When tumors no longer respond to hormonal therapy, chemotherapy or radiation is 
commonly used to relieve symptoms [4]. 
 
 
 
1.2 TUMOR MICROENVIRONMENT 
For many years, cancer research has mainly focused on the cancer cells. However, 
other components of tumors are now becoming established as important factors for 
cancer growth and progress. These components consist of e.g. blood vessels and 
pericytes, lymph vessels, cancer associated fibroblasts (CAFs), immune cells, 
adipocytes and extracellular matrix (ECM) [22,23]. Below follows a short introduction 
to blood vessels, immune cells and ECM in tumors, and a more thorough description of 
CAFs. 
 
 
1.2.1 Tumor vessels 
As other tissues, tumors are dependent on vessels to deliver oxygen and nutrients and 
for removal of waste products. Hence, the ability to recruit vessels is an important and 
growth limiting step for tumors.  The angiogenic process is normally tightly regulated. 
However, the hypoxic conditions and dysregulated production of angiogenic factors 
that are common in tumors stimulate angiogenesis [24]. 
 
Tumor vessels differ from normal vessels in several ways. They have a chaotic and 
irregular shape and are often twisted and leaky. New vessels are also constantly formed 
[24,25]. Experimental data have shown that endothelial progenitor cells are recruited 
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from the bone marrow and contribute to tumor vessels and affects tumor growth 
[26,27]. Besides endothelial cells, tumor vessels have been reported to contain also 
cancer cells, giving rise to what is referred to as mosaic vessels [28]. There are also 
reports of genetic instability and altered gene expression in tumor vessels [29,30]. 
 
Apart from being a requisite for tumor progression, vessels are also a common route for 
tumors to metastazise. 
 
Targeting of tumor angiogenesis by the use of VEGF-inhibitors are in clinical use for 
treatment of renal, breast, colorectal and lung cancers [31,32,33,34]. 
 
Pericytes are perivascular cells, known to be involved in for example vessel maturation 
and remodelling [35]. Tumor pericytes are different from their normal counterparts. 
Tumor vessels are commonly covered by fewer pericytes, which are more loosely 
attached. The expression of markers also differs from that of pericytes in normal tissues 
[36].   
 
The significance of pericytes in cancer is not clear. Some studies have demonstrated 
that reduced pericyte coverage in tumor vessels is associated with an increased risk of 
tumor metastasis [37,38]. Other studies show that increased coverage of pericytes on 
tumor vessels enhances tumor growth [39,40].  
 
 
1.2.2 Immune cells 
The association between cancer and inflammation is substantiated in many different 
tumor types. Inflammation leads to accumulation of various immune cells, contributing 
to cancer in various ways. How different immune cells influence tumors is not 
completely sorted out. A polarization of immune cells in tumors, leading to a more pro-
tumorigenic phenotype, is commonly observed [41]. The literature concerning immune 
cells and cancer is vast and complicated and below follows a few examples of the 
involvement of immune cells in cancer. 
 
Some immune cells, such as cytotoxic T-cells and NK cells are usually associated with 
targeting and suppression of malignant cells, whereas others such as mast cells, 
myeloid cells, granulocytes and macrophages can enhance tumor growth [42]. 
Macrophages have also been shown to be involved in tumor metastasis [41]. 
 
Presence of macrophages in tumor tissue is correlated with bad prognosis in many 
cancers such as breast, skin and cervix cancers [43,44,45]. However, in colon cancer, a 
high infiltration of macrophages is associated with a better outcome [46]. It is possible 
that markers with the ability to distinguish between different macrophage subsets 
would sort out these contradictory results. 
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1.2.3 The ECM 
The ECM is mainly composed of proteoglycans, collagens, hyaluronan, fibronectin, 
elastin and laminin. The role of the ECM is to provide e.g. support, structure and 
anchorage for cells and to sequester proteins such as growth factors.  In the normal 
tissue, degradation and production of ECM components are tightly regulated. When 
tumors grow and invade into tissues, the ECM is degraded by proteases produced by 
cancer cells and stromal cells, leading to release of proteins that can influence tumor 
growth and progression [47]. 
 
The basement membrane (BM) is a form of ECM, surrounding the epithelium of tissues 
and thereby organizes the epithelial layer and forms a barrier to the neighboring tissue. 
A tumor is defined as being invasive when the BM is degraded and the cancer cells 
infiltrate the stroma. The cleaved fragments from the BM are known to regulate 
angiogenesis [48,49].  
 
 
1.2.4 CAFs 
Stromal changes occurring during the development of many solid tumors is a well 
known phenomenon. These changes often consist of an increased fibroblast 
proliferation and production of ECM constituents. The fibroblasts in a tumor, often 
termed CAFs, have a specific phenotype including the expression of stress fibers and a 
number of markers such as FAP, FSP, α-SMA, PDGFRα, PDGFRβ and NG-2 [50,51]. 
The CAF population is heterogenous and it is likely that a number of different subsets 
of CAFs exist [52].  
 
The specific phenotype of CAFs is very similar to fibroblasts observed in wound 
healing and fibrosis. The prominent function of fibroblasts in wound healing is to 
generate ECM components and contracting the wound. In response to wounding, 
fibroblasts are recruited and acquire the activated phenotype. After the wound is healed, 
the normal phenotype is restored. However, during tumorigenesis, they stay constantly 
active. This has led to the concept of tumors as “wounds that do not heal” [53].  
 
1.2.4.1 Recruitment of CAFs 
 
The origin of CAFs is not completely clear. One suggestion is that fibroblasts already 
present in the tissue are converted to the activated phenotype by signals from other 
tumor compartments [54]. Different growth factors, such as TGFβ, PDGF, FGF-2 and 
hedgehog are thought to be involved in the activation of fibroblasts [55]. The effects of 
TGFβ and PDGF are thought to have the greatest influence, and their effect on tumor-
stroma interactions have been extensively studied.  
 
Some experimental studies, where transplanted bone marrow genetically different from 
the host was used, also indicate that a proportion of the CAF population is originating 
from the bone marrow [56]. Additional support for this hypothesis is provided by the 
  8 
finding that human bone marrow derived mesenchymal stem cells obtain a CAF-like 
phenotype and CAF-properties when exposed to conditioned medium from cancer cell 
lines [57]. 
 
EMT and EndMT are other suggested sources of CAFs. Evidence for the contribution  
Figure 3. Suggested origins of CAFs. Figure adapted from [51]. 
 
of EMT to the fibroblast population have been shown in renal fibrosis models and 
support for EndMT has been found both in vitro and in animal tumor models 
[58,59,60]. 
 
 
1.2.4.2 Genetic and epigenetic characterization of CAFs 
 
The non-malignant cells of the tumor have generally been considered to be genetically 
stable. However, the observation that the CAF phenotype is maintained in the absence 
of cancer cells motivated analysis of the genetic and epigenetic profile of CAFs from 
different tumors [61].  
 
Some studies indicate that fibroblasts in tumors might carry genetic alterations. Stromal 
cells in breast cancer were shown to have p53 mutations associated with allelic 
imbalance, loss of heterozygosity and lymph node metastasis. Genetic alterations in 
breast cancer were also shown to have stronger associations with clinical characteristics 
than alterations in the cancer cells, suggesting that genetic analysis of stromal cells 
might have clinical relevance in breast cancer [62,63]. Also, analysis of stroma from 
head- and neck tumors from smokers revealed genetic alterations correlating with 
clinical parameters [64].  
 
In contrast, Allinen et al report genetic alterations exclusively in the epithelial cells of 
breast cancer tissue [65]. Analysis of a set of breast and ovarian cancer tissues could 
not detect any genetic aberrations in stromal cells and similar results were found when 
pancreatic CAFs were analyzed [66]. 
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Epigenetic changes in CAFs could be another explanation for the stable CAF-
phenotype. Indeed, epigenetic changes in stromal cells from breast and prostate cancer 
have been demonstrated [67,68].   
 
1.2.4.3 Experimental support for various roles of CAFs in tumor growth 
 
Several different functional studies have shown the importance of CAFs in initiation, 
promotion and metastasis of cancer. CAFs have also been shown to influence the 
sensitivity of tumors to anti-cancer therapies and stem cell properties of cancer cells. 
Below follows a short description of a number of selected studies. 
 
 
Figure 4. Effects of CAFs on the tumor microenvironment. Figure adapted from [51] 
 
Fibroblasts and tumor initiation 
 
In chicken infected with the Rous sarcoma virus, a retrovirus carrying the src 
oncogene, tumors could only be observed at the sites of injection. The oncogene itself 
was not sufficient for tumor formation, but wounding and activation of the fibroblasts 
was necessary. This provides evidence that the tumor microenvironment supply the 
epithelial cells with factors essential for tumor formation [69]. 
 
In another study, the mammary fat pads of mice were cleared from epithelial cells in an 
early stage of development. The mice were then irradiated before the epithelial cells 
were reintroduced. Compared to the non-irradiated group, the irradiated mice 
developed a significantly higher number of tumors, indicating that radiation-induced 
damage of stromal cells influence tumor formation [70].  
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There are also various different co-injection models where cancer cell-lines are 
combined with fibroblasts before injection into immunosuppressed mice. In one study, 
five different human low-malignant cancer cell lines were injected alone, or combined 
with mouse fibroblasts before injection. The addition of fibroblasts reduced the latency 
and increased the frequency of tumors [71]. Subsequent experiments analyzed the 
effect of combining human cancer cells with fibroblasts of different origin. The 
conclusion was that different fibroblasts vary in their potential to promote tumor 
growth [72]. In another study, the properties of human primary prostate cultures of 
CAFs and normal fibroblasts were evaluated. The combination of CAFs and initiated 
prostate epithelial cells displayed a dramatic tumor growth as compared to when 
combined with normal fibroblasts [73]. A similar experiment was performed with 
CAFs and normal fibroblasts isolated from human breast tissue, also indicating a cancer 
promoting effect of CAFs [74].  
 
Genetic approaches have also been used to investigate the importance of stromal factors 
in tumorigenesis. Knocking out the TGFβ receptor II specifically in fibroblasts gave 
mice that developed spontaneous tumors in the prostate and forestomach after a few 
weeks, indicating a disturbed paracrine signaling between the fibroblasts and the 
epithelium [75]. Another study report decreased tumor latency and increased tumor 
incidence in p53 knock-out mice as compared to p53 wild type mice after injection of 
mammary cancer cells, indicating that the genetic status of stromal cells affect tumor 
formation [76]. A recent study show that fibroblast-specific deletion of PTEN leads to 
remodeling of ECM, increased angiogenesis and immune cell infiltration and increased 
tumor growth in a mouse mammary carcinoma model. This effect was associated with 
upregulation of the transcription factor Ets2 following PTEN loss in fibroblasts [77]. 
 
 
Effects of CAFs on epithelial cells 
 
The role of CAFs in tumor metastasis  
 
CAFs have also been suggested to contribute to tumor metastasis. Bone marrow 
derived mesenchymal cells were able to enhance metastatic potential of breast cancer 
cells [78]. This effect was mediated by CCL5, a chemokine produced by the 
mesenchymal cells in response to cancer cell stimulation. Further evidence for the 
importance of stromal factors comes from experiments with mice lacking the gene 
encoding FSP1, a protein known to be upregulated in CAFs. This study demonstrates 
that FSP1 knock-out mice display a lower tumor frequency than wild type mice when 
inoculated with cancer cells and the tumors do not metastasize. Moreover, if cancer 
cells are co-injected with FSP1 wild type fibroblasts, the tumor formation is enhanced 
and the ability to metastasize is restored [79]. Also, pancreatic stellate cells increased 
the tumor forming and metastatic potential of cancer cells in a co-injection model [80].  
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CAF-regulation of stem cell traits in cancer cells 
 
Stromal cells were recently described to be capable of affecting stem cell features of 
cancer cells. In this study, colon cancer stem cells were characterized by high activity 
of the Wnt-pathway. CAFs enhanced the cancer cell Wnt-signaling and CAF-produced 
factors were able to re-install a stem cell phenotype in differentiated cancer cells. The 
finding that nuclear β-catenin could be detected in cancer cells surrounded by 
fibroblasts in human colorectal cancer suggests that this might occur also in human 
cancer [81]. 
 
Effects of CAFs on drug sensitivity  
 
Pancreatic stellate cells have been shown to be able to reduce the cancer cell sensitivity 
to drug and radiation therapy [80]. Another study supporting this data shows that 
coculture with fibroblasts reduced drug sensitivity of pancreatic cancer cells in an IL-1β 
and NO dependent manner [82]. In breast cancer, tumor fibroblasts have been shown to 
influence the tamoxifen sensitivity of cancer cells [83]. A recent study demonstrated 
the involvement of fibroblasts in inducing tyrosine kinase-inhibitor resistance in lung 
cancer cells with activating EGF-R mutations. The fibroblast-induced resistance could 
be abolished by inhibiting HGF-signaling [84].  
 
 
Effects of CAF produced factors on other tumor compartments 
 
CAFs can influence tumor development and progression in many different ways. 
Besides being able of stimulating cancer cells, they also exert effects on tumor vessels, 
immune cells and the ECM [23,51]. 
 
Concerning the effect of CAFs on angiogenesis, fibroblasts and inflammatory cells are 
a major source of VEGF, which is a crucial factor in inducing tumor angiogenesis 
[85,86]. Another important component, known to be involved in the tumor-stroma 
interactions is SDF1α. SDF1α is produced by the CAFs and can promote mammary 
epithelial proliferation, migration and invasion [65]. This factor was further 
investigated in a study where CAF-produced SDF1α was blocked with a neutralizing 
antibody. This resulted in a greatly attenuated tumor growth, caused by reduced 
angiogenesis. The proposed mechanism for this effect was that SDF-1 assists in 
recruiting endothelial progenitor cells to the tumor [74]. Moreover, CAFs have recently 
been shown to have the capacity to induce resistance to anti-angiogenic treatment by 
producing PDGF-CC [87].  
 
It has also been demonstrated that CAFs in different mouse and human tumors express 
a pro-inflammatory expression profile. The study also shows that CAFs are involved in 
the recruitment of inflammatory cells and tumor vessels in an NFκB dependent manner, 
and that this effect is an early event in tumor development [88]. CAFs have also been 
shown to interact with NK cells in tumors and to inhibit their cytotoxic ability [89]. 
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Another study suggest that depletion of stroma-derived S100A4 affects the number of 
infiltrating T-cells in tumors which in turn influence the metastatic potential of cancer 
cells [90]. 
 
CAFs are also known to produce various ECM-components and different proteolytic 
enzymes like MMPs, serine proteases and cathepsins. Proteases are able to modify the 
tumor microenvironment and thereby facilitate migration and invasion of cancer cells 
[91,92,93]. An in vitro study shows how fibroblasts promote cancer cell invasion in the 
ECM by creating tracks in which the cancer cells can follow [94]. 
 
1.2.4.4 Prognostic and response-predicative information in tumor stroma 
 
The possibility of deriving prognostic information from tumor stroma has been 
evaluated with e.g. genetic profiling, gene expression profiling and 
immunohistochemstry.  
 
As mentioned before, genetic alterations in stromal cells of head and neck and breast 
cancers have been shown to associate with clinical characteristics [63,64].  
 
Gene expression analysis of microdissected stroma from a large set of breast tumors 
identified a set of stroma-genes which could predict patient outcome, independently of 
known prognostic factors [95]. Also, a wound healing-signature derived from serum-
stimulated fibroblasts was shown to associate with increased risk of metastasis in breast 
cancer patients [96]. Furthermore, a recent study demonstrates response-predicative 
capacities of stroma-associated genes. High expression of stromal genes was associated 
with resistance to chemotherapy in breast cancer patients [97]. 
 
Immunohistochemical analysis of breast cancer tissue shows that high stromal 
expression of PDGFRβ correlates with worse patient outcome [98]. Another prognostic 
marker in breast cancer stroma is Cav-1. Absence of Cav-1 in breast tumor stroma was 
recently shown to associate with poor clinical outcome [99]. Analysis of AR expression 
in prostate stroma demonstrated that low expression of the receptor in tumor and non-
malignant tissue was associated with bad prognosis [100]. Moreover, a high abundance 
of fibroblasts, identified by αSMA immunoreactivity, correlates with disease recurrence 
in colon cancer patients [101]. Similarly, immunohistochemical analysis of stromal 
FAP expression in colon and pancreatic cancers revealed that high expression of FAP 
was associated with bad prognosis [102,103]. For pancreatic cancers, stromal 
expression of SPARC is also correlated with worse outcome [104]. 
 
Besides from tissue based analysis of prognostic information, detection of cleaved 
basement membrane fragments, such as endostatin, in serum has also been suggested as 
possible stroma-derived biomarkers [49]. 
 
Moreover, in a study where the migratory behavior of skin fibroblasts from patients 
with breast cancer was analyzed, an association between abnormal migratory behavior 
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and family history of breast cancer was found [105]. This finding suggests that a certain 
mesenchymal genotype might predispose for development of cancer. To further explore 
this finding might provide information about risk of developing cancer. 
 
1.2.4.5 CAFs as potential drug targets 
 
Since CAFs are important for many aspects of cancer it would be interesting to explore 
the possibility of therapeutic targeting of CAFs. CAFs are also likely to be more 
genetically stable than cancer cells, and might therefore not be as prone to develop 
resistance. 
 
Targeting of CAFs could be accomplished either by interrupting CAF-derived, tumor 
promoting signals or by direct inhibition of the cells.  
 
Immuno-therapeutic approaches of CAF-targeting have been rather efficient in 
experimental models. By inducing an anti-FAP immune response, tumor growth and 
metastasis of breast and colon cancer cells could be inhibited and tumor drug uptake 
was increased [106]. Also, treatment of xenograft tumors with a therapeutic 
immunoconjugate targeting fibroblasts inhibited tumor growth [107]. In addition, 
inhibition of FAP reduced tumor growth in mouse models of lung and colon cancer and 
the tumors demonstrated a decreased number of CAFs and vessels [108]. A FAP 
antibody has also been tested in patients with colon cancer, demonstrating tumor-
specific location and almost no side effects [109].  
 
PDGF is an important factor for fibroblast growth and recruitment. Effects of PDGF 
inhibition on tumor growth have been studied in several experimental settings. 
Treatment with PDGF inhibitors reduces the interstitial fluid pressure (IFP) and 
increase tumor drug uptake. Also, in a stroma-rich cervical cancer model, imatinib 
treatment reduced tumor growth and tumors demonstrated impaired angiogenesis and 
less pericyte coverage of vessels [110]. Moreover, imatinib combined with cytostatic 
treatment reduced growth and metastasis of colon cancer cells [111]. However, since 
imatinib is not only targeting PDGF-signaling, contributing effects by inhibition of 
other pathways cannot be excluded. Nevertheless, the finding that PDGFRβ expression 
in stroma of human breast tumors is associated with bad prognosis motivates further 
studies of inhibition of PDGF-signalling and stromal cells in human cancers. 
 
In addition to PDGF, TGFβ is another growth factor that is important for fibroblast 
recruitment and activation. Fibroblast-specific knock-out of TGFβ receptor II resulted 
in the development of tumors in the prostate and forestomach, demonstrating that 
disturbance of stromal signals is sufficient to cause spontaneous cancer growth [75]. 
TGFβ is known to have both tumor inhibiting and promoting traits, depending on e.g. 
tumor stage and context, hence targeting of TGFβ in cancer might have undesired 
effects [112]. 
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A recent study shows that inhibition of hedgehog signaling specifically in the stroma 
lead to reduced xenograft growth, proposing the hedgehog signaling pathway as a 
potential stroma drug target [113]. Moreover, targeting of stromal cells by inhibiting 
hedgehog signaling improves drug uptake in a pancreatic cancer model [114]. 
 
It is likely that CAF targeting drugs would not be used as a single treatment, but rather 
in combination with conventional treatments. As mentioned earlier, CAFs are known to 
interfere with cancer cell drug sensitivity and to integrate CAFs in the process of 
developing new cancer therapies might be very useful. An interesting recent study 
show how CAFs can be included in drug screening and the study also identifies a drug 
with increased activity in the presence of stromal cells [115]. 
 
 
 
1.3 INTRODUCTION TO PDGF, CXCL14 AND GDF15 
1.3.1 PDGF 
There are five different isoforms of PDGFs (PDGF-AA, -AB, -BB, -CC, and –DD), 
and they signal via PDGF α- and β-receptors. They are secreted as disulfide-bonded 
dimers and contain a conserved motif of eight cysteine residues. The PDGF α- and β-
receptors consists of an extracellular domain controlling ligand binding and receptor 
dimerization, a transmembrane domain and an intracellular kinase domain. In vitro data 
show ligand-receptor interactions between PDGFRα and PDGF-AA, PDGF-BB, 
PDGF-AB and PDGF-CC.  PDGFRβ interact with PDGF-BB and PDGF-DD and the 
heterodimeric receptor binds to PDGF-AB and PDGF-BB [116]. Upon ligand binding, 
the receptor will dimerize and autophosphorylate. This in turn leads to recruitment and 
activation of SH-2 domain containing proteins such as PI3K, Src, SHP-2 and PLCγ, 
finally resulting in cellular responses such as proliferation, migration and survival 
[117].  
 
PDGFs are potent growth factors, stimulating primarily cells of mesenchymal origin 
such as pericytes, fibroblasts, smooth muscle cells and macrophages [118]. Besides 
important regulatory functions during embryogenesis, PGDFs are also involved in 
wound healing processes and regulation of IFP in tissues [119,120,121].  
 
As with many other important growth factors, dysregulation of PDGFs are found in 
different malignancies.  
 
Mutations and translocations affecting PDGF receptors and ligands are not commonly 
found in cancer, but some examples are known. DFSP, a rare sarcoma affecting the 
skin, is caused by fusion of the PDGFB and COL1A1 genes [122,123,124]. GISTs are 
mesenchymal, gastrointestinal tumors, most commonly found in the stomach. In 
approximately 10% of GISTs, activation mutations of PDGFRα are found [125]. 
Fusion of the PDGFRβ gene and the TEL gene is found in approximately 30% of all 
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CMML cases [126]. Also other fusions of PDGF receptors with various genes have 
been identified [127]. In glioblastoma, amplifications of the PDGFRα gene are found 
in 5-25% of all cases [128,129,130].  
 
PDGF receptors and ligands are known to be involved in tumor angiogenesis, mainly 
by mediating the recruitment of pericytes to the vessels. Pericytes are important for 
vessel stability and PDGF-mediated vessel recruitment has been shown to accelerate 
tumor growth [39,40]. Expression of PDGFRβ is a common feature of pericytes in 
most solid tumors [98]. PDGF receptor expression has also been shown in endothelial 
cells from experimental tumors and metastasis [80]. It can however be considered that 
the endothelial expression might rather reflect a perivascular cell expression.  
 
PDGF is also a strong chemo-attractant and mitogen for fibroblasts [131]. The ligand is 
produced by the cancer cells but acts mainly in a paracrine fashion to stimulate cells in 
the tumor stroma. Cancer cells are considered not to respond to PDGF stimulation. 
PDGFRβ is commonly expressed in tumor stroma and receptor expression has been 
shown to associate with prognosis in human breast cancer [98]. There is a great deal of 
experimental data supporting the role of PDGF in stroma formation. Mice injected with 
melanoma cells overexpressing PDGF-B obtain tumors with a higher content of stroma 
as compared to control mice, and similar results have been shown with keratinocytes 
[132,133]. PDGF has also been shown to be important for the development of 
desmoplasia in a xenograft model [134]. 
 
Another feature of solid tumors where PDGF is known to be involved is in the 
regulation of IFP [135]. Treatment with PDGF antagonists in tumor models results in a 
reduction of IFP and enhanced drug uptake [136,137,138,139]. 
 
Imatinib, sunitinib and sorafinib are FDA approved drugs inhibiting PDGF signaling. 
They are not specific for PDGF receptors, but target also a number of other tyrosine 
kinases. Treatment of GIST, CMML and IHES with imatinib has shown good results. 
In addition, promising results from treatment of glioblastoma with HU and imatinib 
have been reported [129].  
 
 
1.3.2 CXCL14 
CXCL14, also referred to as BRAK, MIC-1, MIP-2γ or KS1, is a member of the CXC 
chemokine family. CXCL14 however lacks the N-terminal ELR motif and would 
therefore be predicted to inhibit angiogenesis. The CXCL14 receptor remains to be 
identified [140].  
 
CXCL14 is expressed in most normal tissues, including heart, placenta, lung, brain, 
liver, pancreas, skeletal muscle and kidney. The expression of CXCL14 is however 
absent in many cancer cell lines[141]. In situ hybridization of tumor and adjacent non-
malignant tissue from several different organs show expression of CXCL14 primarily 
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in the epithelium of normal tissues and in the stroma of cancer tissues. Hence, the 
epithelial expression of CXCL14 is commonly lost during cancer progression, whereas 
the expression is induced in stromal cells [140,142] 
 
Biological activities of CXCL14 include chemotactic activity on activated monocytes, 
immature dendritic cells and activated NK cells [142,143]. 
 
Concerning the effects of CXCL14 on cancer growth, present information is 
contradictory. Some studies indicate a growth-inhibitory function of CXCL14, whereas 
others point to a tumor promoting effect.  
 
Data supporting a tumor inhibitory role of CXCL14 includes the absence of CXCL14 
expression in cancer cells and a number of studies also show decreased tumor growth 
as an effect of CXCL14 stimulation in different xenograft models. For example, 
CXCL14 overexpression in prostate cancer cells has been shown to reduce tumor 
growth [143]. Also, expression of CXCL14 in oral cancer cells inhibited tumor growth 
[144]. Moreover, treatment of oral cancer cells with EGF has been shown to reduce 
CXCL14 expression and the same group also demonstrated that treatment of head and 
neck cancer cell lines with the EGF-inhibitor gefitinib increase the levels of CXCL14 
and inhibit xenograft growth [145,146]. Furthermore, epigenetic silencing of CXCL14 
is frequently found in human lung cancer samples, and restoration of CXCL14 
expression reduces growth of lung cancer xenografts [147].  
 
As mentioned before, CXCL14 is lackning an ELR motif, and is therefore expected to 
inhibit angiogenesis. Some experimental data support this hypothesis and demonstrate 
that CXCL14 has anti-angiogenic effects by inhibiting endothelial cell migration [142]. 
 
Since CXCL14 is a potent chemoattractant for immune cells, loss of CXCL14 has also 
been suggested as a way for tumors to escape immune surveillance. 
 
Other studies instead suggest CXCL14 to stimulate tumor growth. Many of these 
studies demonstrate an increased mobility and proliferation of cancer cells upon 
CXCL14 stimulation. CXCL14 is upregulated in myoepithelial cells of breast tumors 
and stimulate proliferation, migration and invasion of breast cancer cells [65]. A recent 
paper shows that reactive oxygen species induce CXCL14 expression in breast cancer 
cells via AP-1 and promote their migratory and invasive properties [148]. In pancreatic 
cancer tissue, upregulation of CXCL14 is commonly found and CXCL14 stimulation 
increased the invasive capacity of pancreatic cancer cells in vitro. Interestingly, the 
CXCL14 expression was frequently located at the invasive front of tumors, which 
might suggest a role for CXCL14 in metastasis mechanisms [149]. In fact, CXCL14 is 
included in a set of genes that can predict time for metastasis of breast cancer [150].  
Moreover, upregulation of CXCL14 in papillary thyroid carcinoma is associated with 
mutational activation of BRAF and lymph node metastasis [151].  
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The conflicting literature of CXCL14 might be explained by the different settings and 
models that are used in the different studies. Receptor identification and subsequent 
analysis of receptor expression might help in resolving this. The role of CXCL14 in 
cancer is likely context dependent, and microenvironment and cancer cell type are 
likely to influence the effect of CXCL14 on tumor growth.  
 
 
1.3.3 GDF15 
GDF15, also designated MIC-1, PTGF, PLAB, PDF and NAG-1, is an orphan member 
of the BMP family of proteins that is included in the TGFβ superfamily [152]. GDF15 
was originally cloned from myelomonocytic cells with the aim of finding genes 
associated with macrophage activation [153]. GDF15 is first produced as an inactive 
pro-peptide, but after disulfide-linked dimerization of the precursor the pro-peptide is 
cleaved by a furin- like pro-protein convertase to release the C-terminal mature GDF15 
protein (112 aa) [152].  
 
GDF15 expression is induced in response to the MAPK signaling pathway [154]. 
GDF15 is also induced and secreted as a response to p53, which might suggest GDF15 
to be a paracrine mediator of p53 signaling [155]. Also other transcription factors, for 
example EGR-1, have been shown to stimulate GDF15 expression [156]. The 
downstream signaling of GDF15 is not completely sorted out, but there are reports of 
SMAD, AKT and ERK activation [152].  
 
Under normal physiological conditions, GDF15 is only expressed at high levels in the 
placenta [157]. However, in response to stress such as injury, inflammation and cancer, 
GDF15 expression is increased [157,158,159].  
 
Like with other members of the TGFβ superfamily, the role of GDF15 in cancer is not 
completely clear. Some studies suggest an antitumorigenic capacity of GDF15, whereas 
others report tumor-supporting effects.   
 
The anti-tumor effects of GDF15 often consist of p53 dependent or independent 
induction of apoptosis and growth arrest. Several in vitro studies and tumor xenograft 
models report decreased growth of cancer cell lines and xenografts when the cancer 
cells overexpress GDF15 [152]. GDF15 has also been shown to inhibit angiogenesis 
[160]. 
 
Support for a tumor-stimulatory role of GDF15 can be found in a number of studies. 
GDF15 is expressed in many different cancer cell lines such as breast, pancreas, colon 
and prostate [159]. Upregulation of GDF15 is also found in many melanoma cell lines 
and GDF15 shRNA can reduce the tumorigenicity of melanoma cells [154]. Increased 
levels of GDF15 in cerebrospinal fluid have been shown to be a marker for 
glioblastoma, and are also correlated with worse outcome of the disease [161]. 
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Furthermore, overexpression of GDF15 can be found in metastatic prostate, breast and 
colon tumors, which in turn leads to increased levels of GDF15 in the serum [159]. 
Serum levels of GDF15 have also been shown to correlate with prostate cancer stage, 
prognosis and presence of bone metastasis [162,163]. Reports of increased serum levels 
of GDF15 in response to cancer progression have also been shown in colon cancer and 
pancreatic cancer [164,165].  
 
Another recent study report an increased actin reorganization and phosphorylation of 
FAK and Rho A as an effect of GDF15 overexpression in cancer cells, which in turn 
leads to an increased motility and metastatic capacity of the cancer cells [166]. 
 
GDF15 has also been shown to be upregulated in human prostate cancers in response to 
chemotherapy. Overexpression of GDF15 in prostate cancer cell lines or treatment with 
recombinant GDF15 induced resistance to chemotherapy [167]. Additional in vitro data 
report that GDF15 protect cells against chemotherapy in a p53-dependent manner, by 
inducing the PI3K/Akt signaling pathway [168].  
 
SNP analysis of the GDF15 gene revealed a polymorphism consisting of a variation 
from a histidine (H) to an aspartic acid (D) at position 6 in the GDF15 protein. The 
homozygous histidine variant is most common (54%), thereafter the heterozygots 
(39%) and least common is the homozygous aspartic acid variant (7%) [169]. These 
different variants seem to influence the risk of developing cancer. Whereas presence of 
the D allele is associated with better survival in an analysis of 200 colon cancer 
patients, the H allele was found to be associated with an increased risk for prostate 
cancer in a study including 1383 prostate cancer patients and 700 controls [164,170].  
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2 PRESENT INVESTIGATION 
Aims: 
 
• To identifiy new diagnostic biomarkers for prostate cancer 
• To find potential prognostic markers and therapeutic targets in prostate cancer 
stroma 
 
Results 
 
Paper I 
 
Diagnostic biomarkers of prostate cancer 
 
Since the sensitivity and specificity of currently used biomarkers for diagnosing 
prostate cancer is not optimal, identification of additional biomarkers would facilitate 
diagnosis in difficult cases. 
 
With the aim of finding markers of diagnostic relevance in prostate cancer, a screening 
was performed in the HPA atlas. The screening resulted in a number of candidates from 
which three novel proteins proteins, CYCS, ICK, IKBKB, were selected for further 
analysis. In addition, AMACR that is an already known diagnostic marker was also 
analyzed. 
 
Expression of these proteins was analyzed with immunochistochemical staining of a 
TMA containing 40 prostate specimens with benign tissues, precursor lesions and 
invasive carcinoma represented from the same cases. Staining intensity and extent was 
then scored. In addition, expression of all four genes was evaluated with qRT-PCR on 
material isolated from fresh frozen tumor and benign prostate tissue from 32 
independent patients. 
 
The immunohistochemical analysis demonstrated that all four biomarkers had an 
increased expression in prostate cancer as compared to non-malignant tissue. The best 
prognostic performance was achieved with IKC and AMACR. 
 
The qRT-PCR analysis could confirm upregulation in cancer of AMACR. However, 
upregulation of CYCS, ICK and IKBKB could only be detected in a minority of cases. 
 
In summary this study shows that AMACR is a useful diagnostic tissue marker for 
prostate cancer, but CYCS, ICK and IKBKB might be useful as additional diagnostic 
markers. 
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Paper II 
 
Stromal PDGFRβ expression in prostate tumors and non-malignant prostate 
tissue predicts prostate cancer survival 
 
The possibility to acquire prognostic information from tumor stroma is being 
increasingly explored and many stroma-derived tissue-biomarkers have been identified.  
High PDGFRβ expression in breast cancer stroma has been shown to associate with 
poor outcome of patients and to further explore this finding in other tumors might 
provide new prognostic tools. 
 
In this study, we analyzed the expression of PDGFRβ with immunohistochemistry on a 
TMA containing tumor and non-malignant tissue from more than 300 prostate cancer 
patients. The staining intensity was scored independently in stroma and around the 
vessels and the results were associated with histopathological data 
 
Expression of PDGFRβ was primarily found in the fibromuscular stroma and in 
perivascular cells. 
 
The perivascular PDGFRβ expression in tumor tissue was found to correlate with 
advanced stage, increased tumor vessel density and high Gleason score. Moreover, the 
perivascular PDGFRβ expression in non-malignant tissue correlated with increased 
epithelial cell proliferation. 
 
PDGFRβ expression in non-malignant and tumor fibromuscular-stroma was associated 
with large tumor size, advanced stage, high Gleason score and reduced cancer-specific 
surivial. In addition, the PDGFRβ expression in non-malignant stroma was also 
associated with increased proliferation of epithelial cells whereas PDGFRβ expression 
in tumor stroma was associated with high vessel density. 
 
Overall, this study identifies a number of previously unidentified associations between 
stromal PDGFRβ expression and clinical parameters, including Gleason score and 
survival. 
 
Paper III and IV 
 
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal 
stimulator of prostate tumor growth and Local and systemic pro-tumorigenic 
effects of fibroblast-derived GDF15  
 
CAFs and other cells in the tumor microenvironment are known to interact with the 
malignant cells and affect tumor growth, progression and metastasis. A number of 
studies have also shown that CAFs influence drug sensitivity of cancer cells and tumor 
drug uptake. Further characterization of CAFs and identification of proteins mediating 
these effects might provide new ways of inhibiting tumors.  
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To determine gene-expression differences between normal fibroblasts and CAFs, we 
performed microarray analysis comparing normal fibroblasts and CAFs isolated from 
prostate cancer tissue.  
 
CXCL14, an orphan chemokine, was found to be 40-fold upregulated in prostate CAFs. 
Another transcript, GDF15 was up-regulated 8-fold. Expression of CXCL14 and 
GDF15 was analyzed with qRT-PCR in additional prostate cancer tissues and 
upregulation of both genes were confirmed in six of eight cases.  
 
To evaluate the functional importance of these genes, we generated fibroblasts 
overexpressing CXCL14 or GDF15. Overexpression of CXCL14 in fibroblasts 
increased their proliferation and migration and co-culture with fibroblasts 
overexpressing CXCL14 stimulated growth and migration of prostate cancer cells. The 
effects on cancer cells could however not be recapitulated by stimulation with 
recombinant CXCL14, indicating that the effects on cancer cells is not triggered by 
CXCL14 but rather some factor/s produced by fibroblasts in response to CXCL14 
treatment. Furthermore, co-injection of fibroblasts overexpressing CXCL14 with 
prostate cancer cells in mice increased xenograft growth as compared to when cancer 
cells were combined with control fibroblasts. The xenograft tumors were characterized 
by increased vessel density and infiltration of macrophages. These results were 
supported by experiments showing that CXCL14 increased migration of monocytes and 
that fibroblasts overexpressing CXCL14 enhanced endothelial cell recruitment. 
 
Similarly, GDF15 overexpression in fibroblasts increased growth of fibroblasts and 
enhanced proliferation, migration and invasion of prostate cancer cells. Also, GDF15 
overexpression in fibroblasts promoted xenograft tumor growth and stimulated tumor 
growth at a distant site.  
 
These studies identify stroma-derived CXCL14 and GDF15 as novel tumor promoting 
factors.  
 
 
Conclusions and future perspectives 
 
Paper I 
 
The conclusion from the first paper is that AMACR is a good tool for detection of 
prostate cancer, but the other markers might help in cases where AMACR fails. 
 
The discrepancy between the results obtained with immunohistochemistry and qRT-
PCR might depend on different things. Either the two sets of patients differ with regard 
to their expression of the markers or the protein levels are not corresponding to mRNA 
levels. A very local increase of expression might be diluted in the qRT-PCR analysis 
and marker expression in the benign stroma could further obscure the data. For this 
purpose, immunohistochemical analysis is probably superior to qRT-PCR analysis 
since information about protein location and distribution can be obtained. 
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Since all four proteins were found to have increased expression in prostate cancer, 
further functional studies might be of interest.  
 
Also, to further explore the potential of CYCS, ICK and IKBKB in cases that are very 
challenging to diagnose would be interesting. One of the analyzed patients was 
negative for AMACR but positive for the other markers, indicating that the CYCS, ICK 
and IKBKB might be used as a complements to AMACR.  
 
Paper II 
 
Expression of PDGFRβ in tumor and non-malignant stroma of prostate tissue was 
associated with a number of clinical charactersitics and shorter cancer specific survival. 
 
In the present study we have analyzed PDGFRβ expression. To instead analyze 
receptor activation might further improve the prognostic capacity. This could be 
achieved by using a recently developed technique, in situ-PLA [171,172]. 
 
The finding that PDGFRβ expression also in non-malignant prostate tissue was 
interesting and might be useful since biopsies sometimes captures non-malignant tissue. 
 
It would also be interesting to understand if PDGFRβ is expressed in normal tissue also 
in other organs. If this is the case, it is possible that these patients carry a specific 
mesencymal phenotype and that this phenotype might predispose for prostate cancer 
and possibly also for other cancers. This topic merits further investigation. 
 
Paper III 
 
CXCL14 was found to stimulate proliferation and migration of fibroblasts. Fibroblasts 
overexpressing CXCL14 was able to enhance growth and migration of prostate cancer 
cells and increase growth of prostate cancer xenografts. 
 
It is possible that macrophages contribute to some of the effects seen in the xenograft 
experiment and also the matrigel plug assay, such as stimulation of angiogenesis. In 
vitro analysis of the effect of conditioned medium from CXCL14 overexpressing 
fibroblasts on endothelial cells might provide more information about this. 
 
Our data indicate that the effects of CXCL14 on cancer cells and angiogenesis is not 
caused by the CXCL14 producing fibroblasts directly but rather by factors produced by 
fibroblasts as a response to CXCL14 stimulation. In this model, the tumor and 
angiogenesis promoting effects of CXCL14 are likely to be fibroblast-dependent. Less 
stroma-dependent models, including other call lines might provide different results. 
 
Identification of the CXCL14 receptor would help to further investigate the context 
dependence of CXCL14 effects. A known receptor would also provide new strategies 
for further analysis of CXCL14 and would also present an additional way of targeting 
CXCL14 signaling. Developing neutralizing antibodies would be another possible 
strategy. 
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To further validate the expression of CXCL14 in human prostate tissue and to analyze 
potential associations between expression and clinical parameters would be very 
interesting. 
 
Paper IV 
 
GDF15 increased fibroblast growth and stimulated proliferation, migration and 
invasion of prostate cancer cells. GDF15 overexpression in fibroblasts enhanced 
prostate xenograft growth and also tumor growth at another site in the mouse.  
 
As for CXCL14, receptor identification and neutralizing antibodies would offer more 
tools for analysis and inhibition of GDF15 function. 
 
Since the cancer cells produce GDF15 themselves, it is not apparent why they are 
stimulated by the fibroblast-derived GDF15. To analyze the differences between cancer 
cell and fibroblast produced GDF15 and investigate the dose-dependency might 
provide more information about this observation.   
 
The assumed systemic, tumor-promoting effect of fibroblast-derived GDF15 needs to 
be further substantiated. Also, the underlying mechanisms should be further explored, 
including analysis of effects of GDF15 on EMT and on recruitment of bone marrow 
derived cells.  
 
To examine the expression of GDF15 in human prostate tissue might provide data on 
possible correlations with histopathological findings. 
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Eva-Stina I hope you will come home some day. Emma, you are such a fun and cool 
person. 
 
The Stockholm friends: Maya, Linda and Sara. I am so happy to have you as friends 
and I love our new tradition with the Castle-Spa-Weekends (including Hanna). 
The families Edman-Almbladh, Wall, Nisancioglu-Patrakka, Wargelius- 
Kullander and Hjälmdahl, for all the fun we have together! 
 
All our friends in Kalmar! 
 
Our familly in Kalmar: Hanns, Wiola and Hans. Thank you for totally spoiling us and 
for all the great vacations we have had together! It’s always so nice to be with you! 
 
My family: mamma, pappa, Anna, Micke, Maja, Ella, and mormor. You all mean 
very much to me and I hope you know it. 
 
Marcus: everything is so fun and easy together with you- I love you! Astrid: you are 
my sunshine! 
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4 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Cancer uppstår som en konsekvens av genetiska förändringar som leder till att celler 
frångår sitt normalt kontrollerade beteende. Orsaker till dessa genetiska förändringar 
kan sällan förklaras enkelt. Man känner dock till en rad olika faktorer som ökar risken 
för att utveckla cancer, som till exempel rökning, solexponering, alkohol, övervikt och 
vissa typer av infektioner. 
 
Prostatacancer är den vanligaste cancerformen i Sverige, med ungefär 9 000 nya fall 
varje år. Sjukdomen drabbar framförallt äldre män. Cirka hälften av patienterna är över 
70 år gamla vid tiden för diagnos och det är mycket ovanligt att drabbas av 
prostatacancer före 40 års ålder. 
 
Diagnosticering av prostatacancer kan ibland vara komplicerat och att hitta nya 
markörer i tumörer för att underlätta detta arbete har varit syftet med ett av projekten. 
Vi har identifierat tre nya markörer som eventuellt kan vara användbara som tillägg till 
de markörer som redan används rutinmässigt. Vidare utvärdering av tillförlitligheten av 
dessa markörer är dock nödvändig. 
 
Tumörer består inte av enbart cancerceller utan även av omgivande stödjevävnad som 
består av till exempel kärl, en sorts stödjeceller som kallas fibroblaster och olika typer 
av immunceller. Denna stödjevävnad kallas ofta för tumörstroma. Cancerforskningen 
har länge koncentrerats på de maligna cellerna, men på senare tid har man förstått att 
även de celler som ingår i tumörstromat är viktiga för bildning och spridning av 
tumörer.  
 
En målsättning har varit att identifiera faktorer i stromala celler i prostatavävnad som 
kan användas för bedömning av prognos och även att hitta nya stroma-producerade 
proteiner som eventuellt kan fungera som mål-proteiner för nya läkemedel. 
 
I våra studier har vi identifierat två proteiner, CXCL14 och GDF15, som produceras av 
tumörfibroblaster i prostatacancer.  Experiment i cell- och djur-modeller har visat att 
dessa proteiner kan stimulera tumörväxt. Fortsatta studier kommer att ytterligare 
undersöka betydelsen av dessa proteiner för tumörväxt. Vi har även funnit att patienter 
som uttrycker ett specifikt protein, PGDFRB, i prostatastroma har kortare överlevnad. 
Eventuellt kan detta protein användas för bedömning av en patients prognos. 
 
Sammanfattningsvis har studierna identifierat nya potentiella diagnostiska markörer för 
prostata cancer och tre olika stroma-producerade proteiner (PDGFRB, CXCL14 och 
GDF15) som förhoppningsvis kan utvecklas till prognostiska markörer och mål-
proteiner för nya läkemedel. 
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